ECE2019 Poster Presentations Pituitary and Neuroendocrinology 1 (72 abstracts)
1Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan; 2Republican Specialized Scientific Practical Medical Center of Endocrinology of Republic of Uzbekistan named by Ya.Kh.Turakulov, Tashkent, Uzbekistan; 3University of Oxford Research Fellow, Green Templeton College, London, UK; 4Saint Bartholomews Hospital, London, UK; 5National Center of Neurosurgery and Neurology, London, UK; 6Liv Hospital, Istanbul, Turkey; 7Ukraine State Medical Institute, Kiev, Ukraine.
Aim: The aim of investigation to determine clinical aggressiveness diagnostic markers in patients with non-functional pituitary adenomas (NFPA), and growth hormone deficiency (GHD) in the formation of gravity neuroendocrine disease symptoms.
Material and methods: We observed in 87 patients (including man 44 women 43) of which have a verified diagnosis of NFPA after surgery 31 which were subjected transnasal adenomectomy of the pituiatary (TAG). Further analysis was performed on these patients, who were followed from 1 to 3 years.
Results: After the analysis of the frequency of remission and relapse NFPA data selectively in patients we studied the correlation between various parameters and the frequency of relapses. NFPA developed the scale of aggressiveness allowed to identify the risk factors of markers on the 3rd degrees, allowing to create a set of measures of tumor growth relapse prevention.
Conclusions: Comparative analysis of the results of our research showed that there was a direct correlation with these markers of aggressiveness flow NFPA as the young age of the patient, the first symptoms of a manifest disease, large tumor size, asymmetry, and the pituitary gland deformation, signs of tumor invasion into surrounding tissue/artery/cavernous sinus, the presence of small-cell and/or dark cell chromophobe adenomas panhypopituitarism.